Drugs · acquisition-cost intelligence
Exforge
amlodipine and valsartan· ingredient amlodipineAngiotensin II receptor blockers (ARBs), plain· AMLODIPINE 10 mg/1; VALSARTAN 160 mg/1; AMLODIPINE 10 mg/1; VALSARTAN 320 mg/1; AMLODIPINE 5 mg/1; VALSARTAN 160 mg/1; AMLODIPINE 5 mg/1; VALSARTAN 320 mg/1
What this is. Acquisition-cost intelligence for pharmacy & clinic buyers — the historical trend, generic-equivalent costs, and Part D posture. NADAC is a pharmacy acquisition cost (the national average pharmacies pay), not a retail or cash price — for consumer cash prices use GoodRx/your plan.
Acquisition benchmark · NADAC per EA
$0.48831
NADAC — pharmacy acquisition cost, not a retail/cash price
Acquisition-cost history
Weekly NADAC per EA — the trend nobody else shows. 8 weeks.
2025-01-142026-05-20
Same-ingredient options by acquisition cost
Other amlodipine products, cheapest acquisition cost first. Per EA — confirm strength/form equivalence before switching.
| Product | NADAC / EA | vs this |
|---|---|---|
| AMLODIPINE BESYLATE 10 mg | $0.01136 | −$0.47700 |
| AMLODIPINE BESYLATE 10 mg | $0.01545 | −$0.47290 |
| Lotrel | $0.11766 | −$0.37070 |
| Amlodipine and Benazepril Hydrochloride | $0.14444 | −$0.34390 |
| Amlodipine and Olmesartan Medoxomil | $0.29530 | −$0.19300 |
| OLMESARTAN MEDOXOMIL, AMLODIPINE and HYDROCHLOROTHIAZIDE | $1.23 | +$0.74220 |
| Caduet | $1.41 | +$0.92590 |
| telmisartan and amlodipine | $2.85 | +$2.36 |
Medicare Part D coverage · CY2026
On 318 plan formularies · typical tier 1
Prior auth 0% · Step therapy 0% · Quantity limit 56% of formularies
Sources: CMS NADAC (pharmacy acquisition cost), FDA NDC + RxNorm (identity), RxClass (therapeutic class), CMS Medicare Part D formulary (coverage). Observed reference data for professional buyers — not a retail/cash price, not pricing or medical advice. Verify before purchasing or substituting.